Day: November 3, 2025

Phase III ALLEGORY study met primary and all key secondary endpoints with Gazyva/Gazyvaro, an anti-CD20 monoclonal antibody designed for enhanced B cell depletion Gazyva/Gazyvaro has the potential to be a transformative new standard of care for up to 3.4 million people affected by systemic lupus erythematosus (SLE) worldwide If approved, Gazyva/Gazyvaro would be the first anti-CD20 therapy for SLE to directly target B cells, a key driver of inflammation and disease activity1 These positive results follow the recent US FDA approval and positive EU CHMP opinion for Gazyva/Gazyvaro in lupus nephritis, alongside positive phase III data from the INShore study in idiopathic nephrotic syndromeBasel, 3 November 2025 – Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today statistically significant and clinically meaningful results from the...

Aktsiaselts Infortar acquired its own shares on the Nasdaq Tallinn Stock Exchange during the period of 27–31 October 2025 as follows:Date Aggregated volume (pcs) Weighted average price per day (EUR)27.10.2025 460 40,872628.10.2025 462 40,800029.10.2025 457 40,775930.10.2025 439 40,900031.10.2025 445 40,9000Aktsiaselts Infortar is acquiring its own shares based on the stock exchange announcement published on 20 October 2025. The share buyback programme is managed by SEB Pank AS, which will buy back shares on behalf of Aktsiaselts Infortar. Summary data (daily volume and weighted average prices) will be disclosed no later than on the seventh trading day following the transaction and be made available to the Estonian Financial Supervision and Resolution Authority, via the Nasdaq Tallinn system, and on Aktsiaselts Infortar´s...

Poster presentation outlines potential of CD3 Switch-DARPin T cell engager (TCE) using an AND-gate to overcome limitations of other TCEsDemonstrated selective T cell cytotoxicity against cells co-expressing tumor-associated antigens MSLN and EpCAMInduced significant tumor regression in vivo without causing systemic cytokine release, indicating favorable safety profileZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) — Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics (“Molecular Partners” or the “Company”), today announced it will present further preclinical proof-of-concept data on its logic-gated CD3 Switch-DARPin T cell engager (TCE)...

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) — Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics (“Molecular Partners” or the “Company”), today announced it will present updated data from a Phase 1/2a trial of MP0533, a novel, multispecific T cell engager for acute myeloid leukemia (AML) patients, in a poster at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition, taking place December 6-9, 2025, in Orlando, Florida, and online. The poster will outline latest results of this first-in-human, multicenter, open-label study evaluating MP0533 in relapsed/refractory AML and myelodysplastic syndrome (MDS)/AML patients (ClinicalTrials.gov:...

Vivoryon Therapeutics N.V. to Present at Upcoming Conferences Halle (Saale) / Munich, Germany, November 3, 2025 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company developing small molecule medicines for inflammatory and fibrotic disorders, with a primary focus on kidney diseases, today announced that the Company’s management will participate in the following medical and investor conferences in November: American Society of Nephrology (ASN) Kidney Week 2025Date: November 5 – 9, 2025Location: Houston, TX, USATitle: “Correlation of eGFR and pE-CCL2 in Older Adult Patients Treated with Varoglutamstat: Data from VIVIAD, a Phase 2B Randomized Clinical Trial”Presentation Time: Thursday, November 6, 10:00 am – 12:00 pm CST / 5:00 pm – 7:00 pm CETSession: Late-Breaking Research...

Corbion hereby reports the transaction details related to its share buyback program announced on 1 September 2025. During the week of 27 October up to and including 31 October 2025 a total of 102.003 shares were repurchased at an average price of €17.6450 for a total amount of €1,799,838.05 To date, the total consideration for shares repurchased amounts to 420,203 shares representing 72.40% of the overall share buyback program. Corbion publishes on a weekly basis every Monday, an overview of the progress of the share buyback program on its website: https://www.corbion.com/Investor-relations/shareholder-information This overview contains detailed information on the daily amount of repurchased shares and individual share purchase transactions.Attachment2025 SBB weekly update 20251031

Oslo, Norway, 3 November 2025                                                                                                       Ensurge Micropower ASA (“Ensurge” or the “Company”) today announces that the Company has entered into a set of agreements with Corning Incorporated (“Corning”), one of the world’s leading innovators in glass, ceramics, and materials science, to jointly develop ultra-high performance solid-state microbatteries based on Ensurge’s platform.  Ensurge and Corning have entered into a joint development agreement to establish a framework and joint development program for the two companies to collaborate to integrate Corning’s ribbon ceramic materials and process technology with Ensurge’s proven solid-state microbattery architecture (the “Joint Development Agreement”). Together,...

Joint Development Agreement will establish a foundation for ultra-high energy density microbatteries San Jose, California, United States – Ensurge  (OSE: ENSU), a global leader in solid-state microbattery technology, and Corning Incorporated (NYSE: GLW), one of the world’s leading innovators in glass, ceramics, and materials science, today announced a set of agreements to jointly develop Ensurge’s ultra-high performance solid-state microbatteries. The agreements establish a framework for the two companies to integrate Corning’s Ribbon Ceramic materials and process technology with Ensurge’s proven solid-state microbattery architecture. Together, the two companies aim to deliver an ultra-high energy density product line extension to commercialize batteries that power high-volume consumer, medical, industrial, and defense...

Faraday Future Appoints Chris Nixon Cox as Global Strategic Advisor to Accelerate Global Expansion of “EAI + Crypto” StrategyFaraday Future Founder and Global Co-CEO YT Jia (L) Congratulates Chris Nixon Cox (R) on Becoming a Global Strategic Advisor for Faraday Future.Faraday Future Appoints Chris Nixon Cox as Global Strategic Advisor to Accelerate Global Expansion of “EAI + Crypto” StrategyFaraday Future Appoints Chris Nixon Cox (front row, second from right) as Global Strategic Advisor to Accelerate Global Expansion of “EAI + Crypto” Strategy. Mr. Cox will strengthen global investor relations, government affairs, and industrial partnerships and will join the planned FFAI Global Strategic Advisory Council.Mr. Cox will strengthen global investor relations, government affairs, and industrial partnerships and will join...